Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.
It could also eat into Merck's Pneumovax sales.
A greenlight could garner Pfizer $1B in sales.
The meningitis and encephalitis medications earned a combined $300 million last year.
A study shows that veering off the recommended vaccination schedule ups the risk for childhood seizures.
The CDC said Thursday that most of the 288 recent US measles cases were caused by un-vaccinated travelers who brought the virus home with them.
The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.
The Las Vegas twosome give the anti-vaccination movement their signature treatment.
Researchers find public service announcements and physician information don't change minds, but a California practice found one way it could.
Pfizer hit its endpoints for preventing pneumonia among the elderly, but the data may not be robust enough to spur vaccination.
Queensland, Australia, researchers find the risk of high-grade cervical abnormalities fell 46% among women who had received all three doses of the HPV vaccine.
Ten percent of surveyed doctors told the Centers for Disease Control that reimbursement rates are not enough.
The drugmaker revealed efficacy data that analysts say could prompt the health agencies to emphasize adult vaccination.
The drugmaker's new vaccine has more brawn, but vaccination rates among boys and girls remain low.
Hitting a vaccination rate of 80% of girls would mean 53,000 fewer cases of cervical cancer.
Echoing a strategy similar to that posed by Merck, the drug maker told investors that its strategy for hitting revenue targets includes efficiencies. It also depends on a regulatory-friendly pipeline.
The midnight shutdown put 800,000 government employees on leave, including those at the FDA, NIH and CDC.
The company will "fill the bag" of its sales reps, as part of a reorganization that also includes 8,500 job cuts and a more refined R&D focus.
The Kimberly-Clark-backed cold and flu predictor mixes Big Data, and big branding, with an individualized focus.
The FDA approved GlaxoSmithKline's second quadrivalent flu vaccine, but a CVS study indicates that consumers are big fans of the vaccination, as long as they aren't the ones rolling up their sleeves.
GSK seeks a new ovarian cancer indication for Votrient; a bill that would extend exclusivity for some combination drugs is introduced in Congress; Otsuka's tolvaptan gets a thumbs-down from an FDA advisory committee; NICE rejects Roche's Perjeta; India tosses Herceptin patents; and China revokes Gilead's patent on Viread
Quarterly sales fell 11% compared to the same period last year. The company plans on weathering a continued flow of patent losses with a narrower R&D focus.
The CDC says HPV vaccination rates are not improving. The latest data comes just as a recent report shows the vaccine cannot only help fend off cervical cancer, but throat cancers as well.
FDA grants Teva three years exclusivity to sell Plan B OTC for all ages; FDA gives Humira a thumbs-down for spondyloarthritis; a UK vaccine committee rejects Novartis' meningitis B shot; and Wockhardt gets a warning letter from FDA for its manufacturing practices at an Indian plant.
GlaxoSmithKline second-quarter sales rose 2% over the same period last year. CEO Andrew Witty says it is too early to tally the impact of China's corruption allegations.
China alleges GSK foul play; a report links Incyte's Jakafi with PML; Pfizer gets a double-dose of good Prevnar news; Europe puts almost $29B toward research.
GlaxoSmithKline says it is scaling back on acquisitions; Sanofi's CEO picks a regulatory fight; Maine wants to allow Ex-US meds; and New York State seeks to empower pharmacists.
Analysts say Novo Nordisk's Victoza should brace for Eli Lilly competition; Lilly halts an Alzheimer's study; and Japan reverses its HPV vaccination stance.
Amgen and Astellas team up to take on Japan; GSK acquires Swiss vaccine developer's innovative platform; Ireland makes generic switches easier; Novo backs wet AMD therapy; Nike ditches Livestrong
Welcome to the ambivalent world of healthcare, where confusion reigns as shifts in science and guidelines seemingly raise more questions than they answer.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.